Medicine compound for treating myocardial ischemia reperfusion of rat and application method

A technology of myocardial ischemia and application method, which is applied in the direction of drug combination, pharmaceutical formula, cardiovascular system diseases, etc., can solve the problems of incomplete cell morphology, high cell apoptosis rate, poor treatment effect, etc., and achieve the purpose of improving anti-oxidation Performance, regulating glucose and lipid metabolism, reducing inflammation and oxidative stress effects

CN106310228AInactive Publication Date: 2017-01-11HEBEI UNIVERSITY
5 Cites 3 Cited by

Patent Information

Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Publication Date
2017-01-11
Estimated Expiration
Not applicable · inactive patent

Smart Images

  • Figure 1
    Figure 1
Patent Text Reader

Abstract

The invention discloses a medicine compound for treating myocardial ischemia reperfusion of a rat, belonging to the technical field of the medicine compound for preventing and controlling myocardial infarction. The medicine compound for treating myocardial ischemia reperfusion of the rat comprises the following ingredients: 5-15 parts of astragalus extract, 5-10 parts of salvia miltiorrhiza, 2-5 parts of carthamus tinctorius, 1-3 parts of rhodiola rosea, 0.25-0.75 part of procyanidine, 0.25-0.75 part of adiponectin and 1-2 parts of puerarin. According to the medicine compound for treating myocardial ischemia reperfusion of the rat and an application method thereof provided by the invention, the myocardial ischemia reperfusion injury can be obviously relieved; procyanidine which has the effect of relieving inflammation and oxidative stress is added into the medicine compound, so that the oxidation resistance of a body can be promoted; adiponectin has the functions of regulating glucolipid metabolism, resisting inflammation and resisting atherosclerosis; the medicine compound has the function of protecting rat myocardium; the medicine compound can greatly reduce the apoptosis rate of the cells and protect the complete form of the cells.
Need to check novelty before this filing date? Find Prior Art

Description

technical field

[0001] The invention relates to the technical field of pharmaceutical compositions for preventing and treating myocardial infarction, in particular to a pharmaceutical composition for treating myocardial ischemia-reperfusion in rats and an application method. Background technique

[0002] Myocardial infarction has a high incidence and disability rate, and is one of the diseases that threaten human health. Studies have shown that not only myocardial cell necrosis occurs after myocardial ischemia, DNA damage and apoptosis can be induced around the ischemic area due to the mild damage and the establishment of collateral circulation. Myocardial ischemia-reperfusion injury is the cause of myocardial The common cause of damage is that the existing drugs for the treatment of myocardial ischemia-reperfusion are not effective, and the cell morphology is not complete, resulting in a high rate of apoptosis. Therefore, we propose a drug for the treatment of myocardial is...

Examples

Embodiment 1

[0027] The application method of the pharmaceutical composition for treating myocardial ischemia-reperfusion in rats comprises the following steps:

[0028] S1: Material selection: select 10 healthy male rats;

[0029] S2: Drug administration: The rats selected in S1 were gavaged with a pharmaceutical composition once a day for one week, wherein the amount of the pharmaceutical composition was 6 parts of Astragalus extract, 8 parts of Salvia miltiorrhiza, 2.5 parts of safflower, 2.5 parts of Hongjing 2.8 parts per day, 0.3 parts of proanthocyanidins, 0.7 parts of adiponectin, and 1 part of puerarin;

[0030] S3: establishing a perfusion model;

[0031] S4: Perfusion: Use perfusate for perfusion under constant temperature and pressure, and continuously inject mixed gas;

[0032] S5: Measurement indicators: measure left ventricular developmental pressure and coronary artery flow, observe the incidence of malignant arrhythmia, detect cell apoptosis and the expression of apoptos...

Embodiment 2

[0035] The application method of the pharmaceutical composition for treating myocardial ischemia-reperfusion in rats comprises the following steps:

[0036] S1: Material selection: select 10 healthy male rats;

[0037] S2: Drug administration: The rats selected in S1 were gavaged with a pharmaceutical composition once a day for one week. 1.2 parts per day, 0.73 parts of proanthocyanidins, 0.3 parts of adiponectin, 1.9 parts of puerarin;

[0038] S3: establishing a perfusion model;

[0039] S4: Perfusion: Use perfusate for perfusion under constant temperature and pressure, and continuously inject mixed gas;

[0040] S5: Measurement indicators: measure left ventricular developmental pressure and coronary artery flow, observe the incidence of malignant arrhythmia, detect cell apoptosis and the expression of apoptosis-related protein Bax / Bcl-2;

[0041] S6: Summary: According to the test index, the optimal composition of the drug mixture is obtained.

Embodiment 3

[0043] The application method of the pharmaceutical composition for treating myocardial ischemia-reperfusion in rats comprises the following steps:

[0044] S1: Material selection: select 10 healthy male rats;

[0045] S2: Drug administration: The rats selected in S1 were administered orally with a pharmaceutical composition once a day for one week. 2 parts per day, 0.5 parts of proanthocyanidins, 0.5 parts of adiponectin, 1.5 parts of puerarin;

[0046] S3: establishing a perfusion model;

[0047] S4: Perfusion: Use perfusate for perfusion under constant temperature and pressure, and continuously inject mixed gas;

[0048] S5: Measurement indicators: measure left ventricular developmental pressure and coronary artery flow, observe the incidence of malignant arrhythmia, detect cell apoptosis and the expression of apoptosis-related protein Bax / Bcl-2;

[0049] S6: Summary: According to the test index, the optimal composition of the drug mixture is obtained.

[0050] Based on...